SubsidieMeestersNovel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
The project aims to develop a novel treatment for celiac disease using a combination of gliadin protein, probiotic particles, and mouth patch technology, targeting market entry by 2029.
Projectdetails
Introduction
Celiac disease is an autoimmune indication for which there is no cure. Only the life-long avoidance of the disease-causing gliadin protein in gluten is available as a sub-optimal and cumbersome necessity for CD patients.
Project Development
We developed a unique novel combination of antigen (gliadin protein), probiotic tolerogenic bacterial particles (TBPs), and mouth patch technology to enhance the bioavailability and tolerance induction.
Synergistic Properties
The synergistic tolerizing properties of the TBP-antigen combination and the therapeutic effect of the SOMIT concept have been shown in a suitable pig model. Our SOMIT-CD promises to require a short-course weekly treatment for less than 3 months in CD patients.
EIC Project Goals
This EIC project will allow us to finalize the various preclinical activities and perform a phase Ib/IIa clinical study, paving the way to closing a co-development deal with a big pharma player.
Market Objectives
After market entry in 2029, we aim to:
- Reach a market share of 15%
- Generate annual revenues of €148M by 2033.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.993 |
| Totale projectbegroting | € 3.571.428 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ALLERO THERAPEUTICS BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
First ever preventive treatment for celiac disease and gluten sensitivityE40 is a novel gluten-degrading enzyme designed to improve quality of life for Celiac and gluten-sensitive individuals by reducing gluten's inflammatory effects during digestion. | EIC Accelerator | € 2.499.999 | 2023 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
First ever preventive treatment for celiac disease and gluten sensitivity
E40 is a novel gluten-degrading enzyme designed to improve quality of life for Celiac and gluten-sensitive individuals by reducing gluten's inflammatory effects during digestion.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Controlling immunity with small molecules for a better therapyThe IMMUNOCON project aims to advance EMT-224, an immune activator, towards clinical trials to improve treatment options for late-stage colorectal cancer by converting 'cold' tumors into 'hot' ones. | EIC Transition | € 2.484.700 | 2025 | Details |
Tracking gluten immunoreactive peptides from the grain to the gut and beyondGLUTENOMICS aims to identify and analyze gluten immunoreactive peptides in human biosamples to improve grain-based food tolerability and prevent wheat-related disorders. | ERC Starting... | € 1.499.988 | 2022 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2023 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Controlling immunity with small molecules for a better therapy
The IMMUNOCON project aims to advance EMT-224, an immune activator, towards clinical trials to improve treatment options for late-stage colorectal cancer by converting 'cold' tumors into 'hot' ones.
Tracking gluten immunoreactive peptides from the grain to the gut and beyond
GLUTENOMICS aims to identify and analyze gluten immunoreactive peptides in human biosamples to improve grain-based food tolerability and prevent wheat-related disorders.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.